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Abstract
Background Essential thrombocythaemia (ET) is a rare
clonal myeloproliferative disorder characterized by a sus-
tained elevation in platelet count and megakaryocyte
hyperplasia. Anagrelide is used in the treatment of ET,
where it has been shown to reduce platelet count. Ana-
grelide is metabolized by cytochrome P450 (CYP) 1A2,
and previous studies of the effect of food on the bioavail-
ability and pharmacokinetics of anagrelide were conducted
prior to the identification of the active metabolite,
3-hydroxyanagrelide.
Objectives The objectives of this study were to determine
the effect of food and caffeine on the pharmacokinetics of
anagrelide and its active metabolite, 3-hydroxyanagrelide,
to monitor electrocardiogram (ECG) parameters following
drug administration, and to document the relationship
between palpitations, ECG changes and caffeine intake
Methods Thirty-five healthy subjects who received 1 mg
of anagrelide following either a 10-h fast or within 30 min
of a standardized breakfast, including two cups of coffee,
were studied.
Results Time to maximum (peak) plasma concentration
(Cmax) of anagrelide was 4.0 h in the fed and 1.5 h in the
fasted group (p \ 0.05); similar results were observed for
3-hydroxyanagrelide. The mean Cmax of anagrelide was
4.45 ± 2.32 ng/mL and 5.08 ± 2.99 ng/mL in the fed/
caffeine and fasted groups, respectively; peak concentra-
tions were higher for 3-hydroxyanagrelide in both the fed/
caffeine and fasted groups. The most frequent adverse
events (AEs) were headache (60 %) and palpitations
(40 %). There were no serious AEs and all ECGs were
normal, although significant reductions in PR interval, QRS
length and QT interval were observed in both groups. Heart
rate increased after anagrelide administration in both fed/
caffeine and fasted states (p \ 0.01); however, increased
heart rate was significantly more frequent in the fed/caf-
feine state than in the fasted state (p \ 0.001 for heart rate
increase in the first hour after drug administration). There
was a trend towards a greater heart rate increase in subjects
reporting palpitations than in those without (mean heart
rate ± SD at 1 h: 10.1 ± 6.4 vs. 8.0 ± 8.4 beats/min
[p = 0.35]; at 4 h: 12.7 ± 7.5 vs. 9.1 ± 8.8 beats/min
[p = 0.10], respectively).
Conclusion We conclude that food/caffeine delayed
absorption of anagrelide. Anagrelide was generally well
tolerated and had small effects on ECG parameters and
heart rate. Caffeine may be implicated in a higher increase
in heart rate and increased frequency of palpitations
observed following administration of anagrelide with food/
caffeine versus fasting.
1 Introduction
Essential thrombocythaemia (ET) is a rare clonal myelo-
proliferative disorder [1] characterized by a sustained
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elevation in platelet count (thrombocytosis) and mega-
karyocyte hyperplasia. Anagrelide is used in the treatment
of ET, where it has been shown to reduce platelet count [2]
and may, therefore, decrease the incidence of thrombo-
haemorrhagic complications [3].
In vitro studies have shown that anagrelide is metabo-
lized by cytochrome P450 (CYP) 1A2 and produces the
active metabolite 6,7-dichloro-3-hydroxy-1,5-dihydro-
imidazol[2,1-b] quinazolin-2-one (3-hydroxyanagrelide)
[4, 5]. Caffeine is a known substrate of CYP1A2 [6] and
the possible effects of the constituents of a normal high-fat
breakfast with coffee on the rate and extent of absorption of
anagrelide, as well as the rate and extent of formation
of the active metabolite, was considered worthy of
investigation.
Clinical experience has shown that palpitations are one
of the most common treatment-emergent adverse events
(AEs) associated with anagrelide use [7]. The palpitations
are usually benign and non-arrhythmia-related and tend
to abate over time, with lower incidences reported during
long-term therapy compared with the initial treatment
phase [8]. This is of particular importance with regard to
3-hydroxyanagrelide, as it has been shown to be a potent
phosphodiesterase (PDE) III inhibitor. PDE inhibitors are
associated with positive inotropy and vasodilation and
may, therefore, result in tachycardia and palpitations [9].
In the present study, when assessing the safety and tol-
erability of anagrelide in the fed/caffeine and fasted state,
it was considered of interest to include the monitoring of
cardiac activity by means of heart rate, blood pressure
and electrocardiogram (ECG) recordings. It was hoped
that by including these assessments an insight into the
relationship between anagrelide metabolism, palpitations,




Healthy Caucasian subjects aged between 18 and 40 years
were eligible for inclusion. Subjects were required to be
within 15 % of ideal weight for sex, height and body frame
size according to the Metropolitan Life Tables. Subjects
were required to be non–smokers (or have stopped smoking
at least 6 weeks prior to study start). All subjects had
negative HIV, hepatitis B surface antigen and hepatitis C
antibody, and no clinically significant or relevant abnor-
malities of medical history, physical examination and
ECG, or clinical or laboratory evaluation (haematology,
biochemistry and urinalysis). All subjects provided written
informed consent prior to entering the study.
2.2 Study Design
This was a phase I, open-label, randomized, two-way
crossover study, which was approved by the ethics com-
mittee at Guy’s Hospital, London, UK and appropriate
local ethics committees, and conducted in accordance with
the principles of the Declaration of Helsinki [10].
Subjects were restricted from strenuous exercise and
consuming alcohol, grapefruit, caffeine or xanthine for
48 h prior to, and for the duration of, each study period.
Subjects were randomized to one of two treatment
sequences and stratified by sex: treatment in a fasted state
followed by treatment in a fed state, or treatment in a fed
state followed by treatment in a fasted state. The two
treatment periods were separated by at least 3 days. Sub-
jects received a single oral dose of anagrelide 1 mg either
following a fast of at least 10 h or within 30 min of a
standardized high-fat breakfast that contained 150, 250 and
500–600 cal from protein, carbohydrate and fat, respec-
tively, as well as two cups of black coffee, each containing
58.8 mg of caffeine. Following dosing, subjects were not
permitted to lie down for 4 h, and were discharged from
the unit 24 h after dosing.
The primary objective of the study was to investigate the
pharmacokinetics of anagrelide and its active metabolite
3-hydroxyanagrelide (particularly its rate of formation)
following administration in fed/caffeine and fasted states.
The secondary objectives included assessment of the safety
and tolerability of anagrelide when administered in fed/
caffeine or fasted states and the determination of the
individual levels of CYP1A2 expression by measurement
of the plasma caffeine:caffeine metabolite ratio and eval-
uation of its relationship to observed 3-hydroxyanagrelide
exposure.
The study was conducted at Guy’s Drug Research Unit
in London, UK. The assessment of cardiovascular side
effects and ECG analyses were performed in the Cardiol-




Blood samples for determination of plasma anagrelide and
3-hydroxyanagrelide concentrations were drawn pre-dose
and then 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6,
8, 12, 16 and 24 h post-dose. The 4-h post-dose sample was
also used for determination of individual expression levels
of CYP1A2 by measuring the ratio between caffeine and
its metabolite, paraxanthine. Plasma concentrations
were determined by liquid/liquid extraction followed by
reverse-phase high-performance liquid chromatography
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and detection by tandem mass spectrometry. There were
eight quality control samples used per test with concen-
tration ranges of 0.05–20 ng/mL for anagrelide and
0.1–40 ng/mL for 3-hydroxyanagrelide, using a sample
aliquot volume of 500 lL. The concentration levels were
0.15, 8, 17.5 and 35 ng/mL for anagrelide and 70 ng/mL
for 3-hydroxyanagrelide (the highest concentration
for each agent was diluted one in two before analysis).
The upper limits of quantification of the analytical
method were 20 ng/mL for anagrelide and 40 ng/mL for
3-hydroxyanagrelide. The lower limits of quantification
were 0.05 ng/mL for anagrelide and 0.1 ng/mL for
3-hydroxyanagrelide.
Pharmacokinetic parameters were determined by non-
compartmental analysis of the plasma concentration data
using WinNonlin Professional version 4.01 (Pharsight
Corporation, Mountain View, CA, USA). The following
pharmacokinetic parameters were determined: time to
reach the maximum (peak) plasma concentration following
drug administration (tmax), maximum (peak) plasma drug
concentration (Cmax), area under the plasma concentration-
time curve from time zero to infinity (AUC?), apparent
half-life of the terminal elimination phase (tz), lag time
before the first measurable plasma concentration (tlag) and
apparent half-life of the absorption phase (tabs). Plasma
concentration analysis was performed by York Bioanalyt-
ical Solutions, York, UK. Pharmacokinetic analyses were
performed by Classic PK, Harpenden, UK.
2.3.2 Statistical Analysis
Statistical analysis was performed using SPSS 14.0 (SPSS
Inc., Chicago, IL, USA) and GraphPad Prism 5.0 (Graph-
Pad, San Diego, CA, USA).
Drug concentrations and pharmacokinetic parameters
were summarized by arithmetic mean, standard deviation
(SD), minimum, median, maximum, coefficient of varia-
tion (CV) and geometric mean. The influence of food on
the pharmacokinetic parameters Cmax, AUC? and tabs for
anagrelide and 3-hydroxyanagrelide was assessed by
analysis of variance (ANOVA) for a two-way crossover
design (WinNonlin). The sequence effect was tested using
the subject-within-sequence effect, and all other effects
were tested using the residual error of the model. All
subjects for whom plasma concentration data were avail-
able in both the fasted and fed/caffeine states were included
in the analysis. The parameters were log-transformed prior
to analysis. Average bioequivalence was assessed accord-
ing to whether or not the lower and upper 90 % confidence
intervals (CIs) for the ratio of the geometric means lay
within the range 0.80–1.25. The influence of food/caffeine
on the parameters tlag and tmax was assessed non-para-
metrically (WinNonlin) according to the procedure of
Koch [11]. The significance of differences between fasted
and fed/caffeine states was assessed at the 5 % level.
AEs were analysed according to study period (i.e., die-
tary status fed or fasted) and overall during the two periods
of observation in the study. For cardiovascular parameters,
means (±SD) are reported for continuous variables. Fish-
er’s exact test or the Chi-squared tests were used to assess
the significance of the differences between proportions. For
the quantitative variables either Student’s t test, the anal-
ysis of variance for a two-way crossover design (Win-
Nonlin) or ANOVA (one-way and two-way, including time
up to 4 h post-dose) repeated measures/Bonferroni were
performed. All probability values are two-tailed.
2.3.3 Safety
Safety assessments conducted at screening and throughout
the study included physical examination, vital signs, bio-
chemistry, haematology and urinalysis. All AEs (related
and unrelated, serious and non-serious) were recorded from
the time the informed consent was signed until the end of
treatment exposure using the Medical Dictionary for Reg-
ulatory Activities (MedDRA) preferred terms. Assessment
of intensity was determined according to the following
definitions: mild—AE is easily tolerated and does not
interfere with usual activity; moderate—AE interferes with
daily activity, but the subject is still able to function;
severe—AE is incapacitating and the subject is unable to
work or complete usual activity. Serious AEs were defined
as any untoward medical occurrence that resulted in death,
or was life-threatening, or required hospitalization or pro-
longation of hospitalization, or resulted in persistent or
significant disability/incapacity, or resulted in a congenital
abnormality/birth defect.
ECG Safety A 12-lead ECG was performed at screening,
check-in, pre-dose, 1, 2 and 4 h post-dose, and at discharge
for each treatment period and follow-up. All traces were
reviewed and any abnormalities, heart rate, PR interval, QRS
length and QT intervals were recorded by an author (L.F.-G.)
blinded to the study period, fasting state and presence of
symptoms. Fridericia’s correction was used to calculate
corrected QT (QTc), QTc = QT/RR0.33, as it is superior to
Bazett’s formula, particularly at low heart rates [12].
3 Results
3.1 Subjects
A total of 35 subjects were enrolled in the study (20 male,
15 female), of whom 34 completed both the fasted-fed/
caffeine and the fed/caffeine-fasted treatment sequences.
One female subject withdrew from the study for personal
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reasons and so did not complete both sequences. Subjects’
demographics are summarized in Table 1.
3.2 Pharmacokinetics of Anagrelide and its Metabolite
Pharmacokinetic parameters for anagrelide and 3-hydroxy-
anagrelide are presented in Table 2. Mean plasma con-
centration-time curves are shown in Fig. 1. Anagrelide was
rapidly absorbed after oral administration, with peak
plasma concentrations reached after a median time of 1.5 h
in the fasting state. After food/caffeine, the median peak
plasma concentration was significantly delayed to 4.0 h
(p \ 0.05) (Fig. 1). The mean Cmax was 5.08 ng/mL
(SD ± 2.99) in the fasted subjects and 4.45 ng/mL
(SD ± 2.32) in the fed/caffeine group, while the mean total
exposure to anagrelide was 13.15 ngh/mL (SD ± 5.61)
versus 15.88 ngh/mL (SD ± 7.03) in the fasted and fed/
caffeine states, respectively (Table 2). Bioequivalence
analysis determined that exposure to anagrelide after food/
caffeine was not equivalent to that in the fasted state (90 %
CI values for Cmax and AUC were 0.75, 1.01 and 1.11, 1.27
respectively). In addition, the tlag before absorption was
significantly increased in the presence of food/caffeine
(p \ 0.05). The elimination of anagrelide from plasma
followed a mono-exponential pattern, with a mean tz of
1.70 h (SD ± 0.86) in the fasted state and 1.85 h
(SD ± 1.02) following food/caffeine.
The tmax of the metabolite 3-hydroxyanagrelide was
similar to that of anagrelide, being reached at a median of
1.25 h in fasting conditions and 4.0 h after food/caffeine
(p \ 0.05). The peak concentrations were higher for the
metabolite than for the parent compound; maximum
concentration was 8.29 ng/mL (SD ± 4.85) in the fasted
state and reduced to 5.93 ng/mL (SD ± 2.81) following
food/caffeine. Bioequivalence analysis of Cmax confirmed
that this was not equivalent between the two states (90 %
CI 0.62, 0.86). As with anagrelide, the tlag before
absorption was significantly increased in the fed state
(p \ 0.05). Total exposure to 3-hydroxyanagrelide was
approximately 2.5 times greater than that for anagrelide
but there was little change between fed and fasted states
(29.67 ngh/mL vs. 29.17 ngh/mL [Fig. 1]), and these
results were equivalent (90 % CI 0.95, 1.11). The plasma
half-life of 3-hydroxyanagrelide was 3.11 h (SD ± 1.26)
in the fasted state and 3.25 h (SD ± 1.60) after food/
caffeine. For both anagrelide and 3-hydroxyanagrelide,
there were small differences between males and females
in mean values of pharmacokinetic parameters, although
these were small in relation to the variation of the
population as a whole. For anagrelide, the overall CV
for Cmax was 59 % and for AUC? was 43 %; for
3–hydroxyanagrelide, CV for Cmax was 59 % and for
AUC? it was 41 %.
3.3 CYP1A2 Status
Visual analysis of plots of anagrelide:3-hydroxyanagrelide
ratios for Cmax, AUC? and tz versus the paraxan-
thine:caffeine ratio showed no evidence for a relationship
between CYP1A2 status and exposure to 3-hydroxyana-
grelide relative to that of anagrelide. Accordingly, no fur-
ther evaluation was conducted.
3.4 Safety
Anagrelide was well tolerated during the study, with no
serious or severe AEs (Table 3) and no withdrawals due to
AEs. Overall AEs were reported by a similar number of
subjects in the fasting and fed/caffeine states (23 vs. 19).
Twenty-seven subjects (77 %) had at least one AE during
the study and 26 subjects (74 %) had at least one treatment-
related AE. In addition, there was one non-treatment-
related AE of moderate severity: a case of urinary infection
in a female subject subsequently treated with amoxicillin.
The most frequently reported AEs were headache (21/35
subjects, 60 %), mild in 17/21 cases and moderate in
4/21; palpitations (14/35, 40 %), all mild; and dizziness
or postural dizziness (9/35, 26 %), all mild. Only five
Table 1 Subject characteristics





fasted (n = 17)
Sex, n
Male 10 10 20
Female 8 7 15
Age, years
Median 23 21 22
Range 19–38 18–28 18–38
Height, m
Median 1.7 1.8 1.7
Range 1.6–1.8 1.6–1.8 1.6–1.8
Weight, kg
Median 67.4 68.5 68.2
Range 57.5–77.5 50.8–81.8 50.8–81.8
BMI, kg/m2
Median 22 22 22
Range 20–25 20–27 20–27
Body frame size, n (%)
Small 12 (67) 11 (65) 23 (66)
Medium 6 (33) 6 (35) 12 (34)
Large 0 0 0
BMI body mass index
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treatment-related AEs were of moderate severity: four
cases of headache and one of vomiting (the moderate
vomiting occurred in a subject who also had moderate
headache). These moderately severe events all occurred
during the fasted treatment period. There was no evidence
to suggest that they occurred in subjects with a parti-
cularly high plasma concentration of either anagrelide or
3-hydroxyanagrelide. There were no clinically significant
changes in laboratory safety tests, vital signs or physical
examination during the study.
3.4.1 Palpitations
Palpitations occurred in more individuals during the fed/
caffeine period (12/34 subjects, 35 %) than during the
fasted period, although the difference did not reach statis-
tical significance (6/35, 17 %; p = 0.09). The mean dura-
tion of palpitations was 231 (SD ± 209) min. The mean
duration of palpitations was higher in the fed/caffeine state
than in the fasted state (252 ± [SD] 218 vs. 194 ± [SD]
204 min), but this difference was not significant
(p = 0.53).
3.4.2 ECG
All ECGs performed were considered normal, including
ECGs performed in subjects experiencing palpitations.
Heart rate increased progressively after anagrelide admin-
istration (p \ 0.001) with a mean peak increase (in
fed/caffeine and fasted subjects) of 10 beats/min at 2 h and
8.5 beats/min at 1 h post-dose (Fig. 2). However, heart rate
increase was higher in the fed/caffeine state than in the
fasted state, although this difference was small and
only significant in the first hour after anagrelide intake
(mean increase of 12.2 SD ± 8.4 beats/min vs. 5.1
SD ± 4.7 beats/min; p \ 0.001 [Student’s t test]; Fig. 3).
There was a trend towards a greater heart rate increase in
subjects reporting palpitations than in those without them
(mean ± SD at 1 h: 10.1 ± 6.4 vs. 8.0 ± 8.4 beats/min
[p = 0.35]; at 2 h 10.3 ± 5.8 vs. 9.9 ± 8.5 beats/min
[p = 0.84]; at 4 h 12.7 ± 7.5 vs. 9.1 ± 8.8 beats/min [p =
0.10], respectively). PR interval, QRS length and QT
interval decreased following administration of anagrelide
(p \ 0.001), whereas there were no significant differences
in QTc. Only QT interval change was influenced by the
food/caffeine, with greater reductions in interval observed

































































Fig. 1 Mean plasma concentration-time profiles of (a) anagrelide
and (b) 3-hydroxyanagrelide, in healthy subjects following either a
10-h fast or within 30 min of a standardized breakfast, including two
cups of coffee
Table 2 Summary of pharmacokinetic parameters
Parameter Anagrelide 3-hydroxyanagrelide
Fasted (n = 35) Fed/caffeine (n = 34) Fasted (n = 35) Fed/caffeine (n = 34)
tmax, h [median (range)] 1.50 (0.50–6.00) 4.00 (0.75–6.00) 1.25 (0.50–6.00) 4.00 (1.75–6.00)
Cmax, ng/mL [mean (SD, CV %)] 5.08 (2.99, 59 %) 4.45 (2.32, 52 %) 8.29 (4.85, 59 %) 5.93 (2.81, 47 %)
AUClast, ngh/mL [mean (SD, CV %)] 12.87 (5.56, 43 %) 15.23 (6.75, 44 %) 28.16 (11.76, 42 %) 27.93 (11.42, 41 %)
AUC?, ngh/mL [mean (SD, CV %)] 13.15 (5.61, 43 %) 15.88 (7.03, 44 %) 29.17 (11.88, 41 %) 29.67 (11.74, 40 %)
tz, h [mean (SD, CV %)] 1.70 (0.86, 51 %) 1.85 (1.02, 55 %) 3.11 (1.26, 41 %) 3.25 (1.60, 49 %)
tlag, h [mean (SD, CV %)] 0.34 (0.26, 76 %) 1.34 (0.89, 67 %) 0.33 (0.26, 80 %) 1.01 (0.99, 98 %)
tabs, h [mean (SD, CV %)] 0.43 (0.43, 51 %) 0.74 (0.31, 42 %) 0.78 (0.85, 110 %) 1.02 (0.53, 52 %)
AUC? area under the plasma concentration-time curve from time zero to infinity, AUClast area under the plasma concentration-time curve from
time zero to the time of the last measurable concentration, Cmax maximum (peak) plasma drug concentration, CV coefficient of variation, SD
standard deviation, tz apparent elimination half-life, tabs apparent absorption half-life, tlag lag time before the first measurable plasma
concentration, tmax time to reach Cmax
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4 Discussion
For the most part, the results of this study confirm previous
findings on the pharmacokinetics of anagrelide and further
demonstrate that anagrelide and its active metabolite,
3-hydroxyanagrelide, have a similar pharmacokinetic pro-
file. In this study, anagrelide was shown to be rapidly
absorbed after oral administration in fasted subjects, but
absorption was significantly delayed and Cmax was slightly
reduced in subjects who had received food/caffeine. Fur-
thermore, overall exposure to anagrelide differed between
the fed and fasted states. Food is known to delay the
absorption of anagrelide, but it has not been previously
reported to influence overall exposure [13].
The recommended starting dosage of anagrelide, and the
starting dose in the Medical Research Council Primary
Thrombocythaemia-1 trial, is 0.5 mg twice daily [7]. It is
recommended that the starting dose should be maintained
for at least 1 week [13] and anagrelide-related palpitations
have been found to generally occur during the first days or
weeks [8]. Accordingly a dose of 1 mg was used in this
study as representative of the recommended starting dose;
however, in clinical practice, most patients receive higher
maintenance doses [8].
The increased heart rate and reduced PR intervals
known to occur following anagrelide administration may
be attributed to the known inhibitory effects of anagrelide
and its active metabolite on PDE III, leading to an increase
in cyclic adenosine monophosphate, a second messenger of
b-adrenergic receptors [14], and ultimately resulting in
anagrelide-related palpitations.
The findings of the current study with regard to palpi-
tations are analogous to a previous study comparing
delayed- and immediate-release formulations of anagrelide,
which found no difference between arms in the incidence of
palpitations despite a lower frequency of AEs with the
delayed-release formulation [4]. In our study, the median
peak plasma concentration was significantly delayed by
food intake. It is possible that this effect of food intake,
similar to the delayed-release formulation, might reduce the
incidence of AEs. On the other hand, the trend towards an
increased incidence of palpitations in the fed/caffeine state
versus the fasted state could be related to the ingestion of
caffeine with the meal, although food and caffeine could
present an opposite effect on the appearance of AEs.
Regarding caffeine, the scientific literature is not conclusive
on the relationship between caffeine and palpitations [15–
20]. However, epidemiological studies have found that
palpitations are significantly associated with coffee con-
sumption [21, 22], with a relative risk of experiencing this
symptom of 1.7 for people consuming 240 mg of caffeine
per day compared with caffeine abstainers [22]. In contrast,
a recent observational study suggests that regular coffee
consumption is associated with reduced arrhythmia [23]. In
this study, the increase in heart rate was slightly higher in
the fed/caffeine group, who also tended to present with
palpitations more frequently. The small increase in cardiac
inotropism and vasodilation and decrease in peripheral
vascular resistance may account for this adverse effect [24].
In the Medical Research Council Primary Thrombocy-
thaemia-1 trial, with a median follow-up of 39 months, pal-
pitations were the only cardiac event more common in the
anagrelide–aspirin arm than in the hydroxycarbamide–aspi-
rin arm (16.6 % vs. 1.7 %) [7]. However, even with this
follow-up of over 3 years, arrhythmias were rare and had a
similar incidence in each treatment group (\2 % in both
cases) [7], confirming that the vast majority of anagrelide-
related palpitations are benign. If an individual patient
presents with anagrelide-related palpitations, an ECG
examination during a period where symptoms are present









AEs after dosing (no.) 83 46 37
Mild 77 40 37
Moderate 6 6 0
Severe 0 0 0
Treatment-related AEs (no.)
Mild 71 37 34
Moderate 5 5 0
Severe 0 0 0
Subjects with at least
one AE [no. (%)]
27 (77) 23 (66) 19 (56)
Subjects with at least one
treatment-related AE [no. (%)]
26 (74) 22 (63) 19 (56)
Subjects with AEs
(MedDRA system organ class preferred term) [no. (%)]
Cardiac disorders
Palpitation 14 (40) 6 (17) 12 (35)
Gastrointestinal disorders
Nausea 2 (6) 2 (6) 0
Nervous system disorders
Dizziness 4 (11) 1 (3) 3 (9)
Dizziness, postural 5 (14) 2 (6) 3 (9)
Headache 21 (60) 19 (54) 8 (23)
Involuntary muscle contractions 2 (6) 1 (3) 1 (3)
Respiratory, thoracic
and mediastinal disorders
Epistaxis 2 (6) 2 (6) 1 (3)
Pharyngolaryngeal pain 4 (11) 2 (6) 2 (6)
MedDRA Medical Dictionary for Regulatory Activities
a One subject completed fasted study period only
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aids differentiation of benign from arrhythmic aetiology.
Moreover, many of the anagrelide-related palpitations sub-
side over time [8]. A study of a representative sample of the
Norwegian working population (n = 1475) found that 10 %
had experienced palpitations during the last month [25]. By
comparison, the self-selected group that comprises healthy
subjects was shown to complain less frequently of a range of
symptoms, including palpitations, than a matched healthy
general population outside the clinical research setting [26].
The incidence of palpitations is known to increase with
age [27] but this is mainly due to arrhythmia-related pal-
pitations [28] and, as previously stated, the majority of
anagrelide-related palpitations are benign [7, 29]. How-
ever, the possibility that the effect of anagrelide on cardiac
rhythm is more pronounced in elderly patients cannot be
excluded.
The data suggest that further studies to better define the
relationship between caffeine, anagrelide and palpitations
are warranted. The present study was not specifically
designed to test the effect of caffeine on AEs and only the
combination of food and caffeine has been investigated.
Although a standard breakfast was used, food and caffeine
could have opposite effects regarding the appearance of
AEs. However, our results show that, compared with ana-
grelide taken in the fasted state, intake with food and coffee
produced lower and delayed peak concentrations in blood.
Despite this, heart rate and ECG changes were more fre-
quent in the fed/caffeine group. Until further data are
acquired, a reduction in caffeine intake may prove to be a
worthwhile strategy in patients receiving anagrelide who
report palpitations. Other potential non-cardiac causes of
palpitations, such as stress/anxiety, alcohol and over-the-
counter or prescription medications should also be explored.
While the reduction in QRS length seen with anagre-
lide was minimal and did not exceed the normal range,
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parameters before and after
anagrelide administration:
(a) heart rate, (b) QRS length,
(c) PR interval, (d) QT interval
and (e) corrected QT interval
(QTc). P value for the ANOVA
test was \0.001 in all cases
except QRS (p = 0.028).
* p \ 0.05 for the comparison
with pre-drug value (Bonferroni
analysis). Error bars = 95 %
confidence intervals
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ionotropic agents, such as catecholamines. This effect has
been explained by greater synchrony in the onset of acti-
vation between different regions of the ventricle [30],
suggesting that the effect seen with anagrelide may be
intraventricular. The small reduction of QT interval
observed with anagrelide has also been described with the
catecholamine epinephrine in healthy subjects [31], and
appears unlikely to be of clinical relevance. Moreover, QTc
remained unchanged, suggesting that the reduction of QT
interval was related to the increase in heart rate. All QT and
QTc intervals, as well as all the other ECG parameters,
were within the normal range (including ECGs performed
in subjects reporting palpitations).
Case reports have been published regarding the associ-
ation of anagrelide therapy with reversible high-output
heart failure, atypical Takotsubo syndrome and reversible
cardiomyopathy [32–36]. However, anagrelide has been
used in patients with previous acute coronary syndromes
[37]. Bearing in mind the ionotropic and chronotropic
properties of this drug, it would seem prudent to assess and
monitor, as appropriate, those patients receiving anagrelide
who have cardiac disease, and to use it with caution in
patients with severe cardiac disease. Although numbers
were too small to permit any reliable comparison between
the AE rates during the fed/caffeine and fasted periods, our
results suggest that anagrelide tolerability, especially with
regard to headaches, was slightly improved by taking it with
food as, in general, AEs were more frequent during the
fasted period than the fed/caffeine period. Corresponding
to the higher peak concentration of anagrelide and
3-hydroxyanagrelide in fasted subjects, all events of mod-
erate severity occurred during the fasted treatment period.
Our work is the first to systematically study ECG
changes alongside pharmacokinetics in fed/caffeine and
fasted subjects receiving anagrelide. These data also pro-
vide a potential explanation for palpitations experienced by
patients taking anagrelide therapeutically, which were the







































































































administration with respect to
the fasted state: (a) heart rate,
(b) QRS length, (c) PR interval,
(d) QT interval and
(e) corrected QT (QTc) interval.
Two-way ANOVA included
fasted state and time up to 4 h
post-dose. In the case of heart
rate and QT interval, the p value
was \0.01 for the fasted state,
time and interaction. In the
cases of PR interval, QRS
length and QTc interval, only
time had a significant effect
(p \ 0.01). PR interval, QRS
length and QT interval
decreased following
administration of anagrelide
(p \ 0.001), whereas there were
no significant differences in
QTc. * p \ 0.001 for the
comparison of fasted versus fed/
caffeine state (Bonferroni
analysis). Error bars = 95 %
confidence intervals
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5 Conclusion
Anagrelide is generally well tolerated in healthy subjects
and has a small effect on ECG parameters and heart rate. The
intake of food/caffeine affected the profile of anagrelide
exposure. Caffeine was not shown to affect the metabolism
of anagrelide by CYP1A2, although it may be implicated in
the higher increase in heart rate and increased frequency of
palpitations reported after food/caffeine intake.
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